ERBB2 and breast cancer: Based on these results, the BC subtypes were classified as follows—HR+HER2−: 126 patients (35.4 %), HR+HER2+: 47 patients (13.2 %), HER2-enriched: 78 patients (21.9 %), and TNBC: 105 patients (29.5 %).